Progenitor Life Sciences, LLC
Harnessing advanced technology to generate pluripotent stem cells for innovative immune cell differentiation and potent cancer-targeting therapies.
Harnessing advanced technology to generate pluripotent stem cells for innovative immune cell differentiation and potent cancer-targeting therapies.
Progenitor Life Sciences, LLC is a biotechnology startup that focuses on harnessing advanced technology to generate pluripotent stem cells for innovative immune cell differentiation and potent cancer-targeting therapies. The company emerged in 2012 and is headquartered in the United States. Progenitor utilizes the Matisse Reprogramming System Technology to create highly pluripotent induced pluripotent stem cells and has subsequently developed methods for immune cell differentiation, with a particular emphasis on Cellular Immunotherapy. The startup has also developed pioneering techniques for targeting cancer cells using chimeric antigen receptor (CAR) constructs. This innovative approach, when combined with the body's immune cells, shows potential as a robust treatment for previously immune-evasive cancers. Progenitor last secured a $110.00K investment in a Seed Round, dated 31 December 2013.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $110.00K | - | 31 Dec 2013 |
No recent news or press coverage available for Progenitor Life Sciences, LLC.
We care about your data, and we'd love to use cookies make your experience better.
